Work

Supplemental Tables from Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer

Year: 2023

Type: supplementary-materials

Abstract: Two supplemental Tables are included in this file. The title of the supplemental tables are: Supplemental Table 1A. Hormone receptor, Her2, p53 and Rb status of breast cell lines examined . Supplemental Table 1B. Cell number and drug concentrations used for concomitant and sequential combination drug treatment.

DOI: 10.1158/1535-7163.22508805.v1

Authors: Natalie A. Jabbour-Leung, Xian Chen, Tuyen Bui, Yufeng Jiang, Dong Yang, Smruthi Vijayaraghavan, Mark J. McArthur, Kelly K. Hunt, Khandan Keyomarsi

Language: English

Topic: Cancer-related Molecular Pathways

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362535330

Cites:

Cited by:

Related to: 10